Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent secondary endpoint results, including PSA progression and time to mCRPC, and safety profile reinforce broad clinical applicabilityPromising Phase 1 data for Novartis actinium-based RLT also presented, supporting two Phase 3 trials and reinforcing Novartis global RLT leadershipBasel, May 31, 2026 - Novarti